Kyverna Therapeutics (KYTX) Interest Coverage Ratio (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Interest Coverage Ratio came in at 1.18 in Q1 2026, up 97.61% YoY from 0.6 in Q1 2025, and up 98.94% on a QoQ basis from 110.65 in Q4 2025.
Powered by 
Analysis
Kyverna Therapeutics (KYTX) Interest Coverage Ratio (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Interest Coverage Ratio data on file, last reported at 1.18 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 97.61% year-over-year to 1.18 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.66 (up 86.73% YoY) and the FY2025 annual result came in at 3.88, up 91.65% from the prior year.
- Interest Coverage Ratio climbed to 1.18 in Q1 2026, from 110.65 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 1.18 in Q1 2026 to a low of 454.83 in Q4 2023.
- A 4-year average of 57.34 and a median of 20.26 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2025 — Interest Coverage Ratio sank 697.53% — and 2026, when it soared 97.61%.
- Tracing KYTX's Interest Coverage Ratio over 4 years: stood at 454.83 in 2023, then jumped by 96.95% to 13.87 in 2024, then slumped by 697.53% to 110.65 in 2025, then jumped by 98.94% to 1.18 in 2026.
- The last three Interest Coverage Ratio figures came in at 1.18 (Q1 2026), 110.65 (Q4 2025), and 2.4 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Kyverna Therapeutics | 505.44 Mn | 505.44 Mn | - | -58.69 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -58.69 |
| Mar 31, 2026 | -62.02 |
| Dec 31, 2025 | -88.47 |
| Sep 30, 2025 | -5,532.43 |
| Jun 30, 2025 | -3,172.14 |
| Mar 31, 2025 | -1,896.32 |
| Dec 31, 2024 | -1,520.04 |
| Sep 30, 2024 | -1,211.56 |
| Jun 30, 2024 | -857.31 |
| Mar 31, 2024 | -667.23 |
| Dec 31, 2023 | -454.83 |
| Sep 30, 2023 | -325.64 |
| Jun 30, 2023 | -289.17 |
| Mar 31, 2023 | -260.11 |